Accord Logo

Intended for UK patients and members of the public

Gemcitabine Concentrate

Active Ingredients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Gemcitabine 100 mg/ml Concentrate for solution for infusion

PL Number:
20075/0235
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Change in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product; Implementation of change(s) for which no new additional data are submitted by the MAH

  • Description of update: The following change(s) has been notified:

    Type IA

    5 x B.III.1 Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. Certificate of suitability

    1. European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph.

    2. Updated certificate from an already approved manufacturer

    • Update the Ph. Eur. Certificate of Suitability for Gemcitabine hydrochloride from the already approved manufacturer:

    • HETERO LABS LIMITED updated from R1-CEP 2009-208-Rev 01 to R1-CEP 2009-208-Rev 02

    • INTAS PHARMACEUTICALS LIMITED updated from R1-CEP 2009-089 - Rev 01 to R1-CEP 2009-089 - Rev 02

    • SHILPA PHARMA LIFESCIENCES LIMITED updated from R1-CEP 2006-222 - Rev 00 to R1-CEP 2006-222 - Rev 01 

    • SCINOPHARM TAIWAN, LTD. updated from R1-CEP 2006-272 - Rev 04 to R1-CEP 2006-272 - Rev 05

    • SCINOPHARM TAIWAN, LTD. updated from R1-CEP 2006-272 - Rev 05 to R1-CEP 2006-272 - Rev 06

     A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)

    • Delete Accord Healthcare B.V., Winthontlaan 200, 3526 KV Utrecht, Nizozemska as Batch release site and batch importation function remains as approved.

    PIL sections updated: Section 6 only.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: